Is It Too Late To Buy Arena Pharmaceuticals?

For years, we have been hearing that obesity is a nationwide epidemic that needs to be addressed. And between the diet regiments and pharmaceutical products, the view increasingly seems to be that the FDA, physicians, and patients see obesity as a medical condition versus a lifestyle issue. This of course, is great for pharmaceutical companies like Arena Pharmaceuticals (NASDAQ: ARNA), whose stock it up over seventy percent on Friday after the Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4 yesterday to approve lorcaserin, a selectiveserotonin 2C receptor agonist.  ARNA focuses on using G-protein-coupled receptors (GPCRs) to examine treatments in areas including cardiovascular, central nervous system, and inflammatory diseases, and lorcaserin is its main product. The stock is held by Daniel Gold, DE Shaw, Israel Englander, and Glenn Russell Dubin.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

The panel felt that it could not completely rule out cardiovascular (CV) and heart valve related (valvulopathy) risks, expressing the opinion that ARNA could do as much as it was allowed to prior to approval for valvulopathy. Apparently, the fact that there was minimal to no rise in blood pressure or heart rate was enough to make the panel pronounce that the issue warranted additional studying after CV approval. But despite ARNA’s belief that its drug has no safety signals, we think the PDUFA date will be pushed back after June 27 to develop a valvulopathy monitoring program. This will probably come after the cardiovascular outcomes trial and a panel-suggested cancer monitoring registry. Management commented that it had only conducted preliminary discussions with FDA regarding post-approval requirements.

ARNA also revised its marketing agreement with Eisai (PINK: ESALY) to include most of North and South America. Post-approval, ARNA’s Swiss subsidiary will manufacture lorcaserin and sell to Eisai for an estimated 31% of the selling price. The partnership began in 2010 to sell lorcaserin in the US, whereby ARNA got $50 million upfront plus up to $160 million in regulatory plus $1.2 billion in sales milestones. If ESALY launches lorcaserin in the US, ARNA should receive around $60 million in milestones. With the favorable panel opinion, we think ARNA will look to strike a European marketing partnership since it lacks a footprint in the region—the companies expanded their marketing deal to cover most of North and South America, but lorcaserin remains unpartnered in Europe. Recall that ESLAY will cover 90% of post-approval clinical trial costs.

The logical target market for lorcaserin is obese (body mass index >30kg/m2) adults. According to some estimates, if you forecast of 1.2% penetration into this market, this would total $1.9 billion in US sales in 2018. Arena’s share of U.S. lorcaserin revenues will probably be around $80 million in 2013, $165 million in 2014 and $650 million by 2018. Estimates for lorcaserin are below estimates of $900mn and $1.8bn respectively for Orexigen’s (NASDAQ: OREX) Contrave and Vivus’ (NASDAQ: VVUS) Qnexa, driven largely by relatively efficacy differences. Note that Qnexa’s PDUFA date was extended to July 17 so it could include data from the REMS program. We don’t expect any material impact of ARNA results on Qnexa or Contrave. Qnexa will likely still be the first to commercialize given better efficacy data, and Contrave still is a few years from commercialization. Given lower efficacy for lorcaserin, it will probably be second to Qnexa, but we think the market size is large enough (estimated peak sales of $1 billion) can support several drugs.

Overall, it appears that lorcaserin has the best safety profile of all the candidates seeking obesity approval though it may need to go through additional trials before approval. We aren’t sure how significant a delay these trials could present, ranging from a few months to several months to a year. That said, lorcaserin has some serious revenue potential in the obesity market. Even if delayed, we anticipate that ARNA will be able to get $60 million in milestone payments from ESLAY and frankly, the obesity market is in need of a drug with the safety profile that lorcaserin has. The drug’s tolerability profile also makes it a good candidate for combination therapy thereby to boost efficacy levels. Most analysts are expecting approval in the second half of the year, and we think that’s reasonable. Incorporating all of the information into our valuation, we think ARNA still holds some upside potential despite a big jump on the announcement—we estimate fair value as between $8 to $9 per share based on a NPV model.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!